Literature DB >> 20658290

Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study.

Theodoros Dimitroulas1, Georgios Giannakoulas, Hariklia Dimitroula, Tilemahos Sfetsios, Despina Parcharidou, Haralambos Karvounis, Loukas Settas.   

Abstract

Systemic sclerosis is a connective tissue disease, which may lead to elevated pulmonary arterial pressure due to pulmonary arterial hypertension and/or left ventricular diastolic dysfunction. Uric acid (UA) has been shown to be elevated in patients with pulmonary hypertension (PH) and heart failure. We aimed to investigate the potent relationship between serum UA and pulmonary pressure as well as functional capacity in patients with SSc. We studied 66 patients (mean age 57.7±12.1years, 63 women), presenting with SSc. Systolic pulmonary artery pressure assessed by echocardiography, lung function tests, six-minute walk test (6MWT) and serum UA levels were recorded in all patients. In 24 (36%) patients, the diagnosis of PH was established by echocardiography (systolic pulmonary artery pressure ≥40 mmHg). Patients with PH had higher UA serum levels compared to patients without PH (5.1±2.1 mg/dl vs. 4.2±0.9 mg/dl, p=0.04). Among patients with PH, UA values were inversely correlated with the SMWT distance (r=-0.51, p=0.01). Serum UA values increased in proportion to the functional capacity in PH patients with scleroderma. Further investigations in prospective studies will unfold in detail the pathophysiological significance of UA in SSc patients with PH and determine its role as a prognostic marker in the assessment and monitoring of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658290     DOI: 10.1007/s00296-010-1557-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.

Authors:  Y Allanore; D Borderie; C Meune; L Cabanes; S Weber; O G Ekindjian; A Kahan
Journal:  Arthritis Rheum       Date:  2003-12

3.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension.

Authors:  D Mukerjee; L B Yap; A M Holmes; D Nair; P Ayrton; C M Black; J G Coghlan
Journal:  Respir Med       Date:  2003-11       Impact factor: 3.415

4.  Hyperuricemia in severe pulmonary hypertension.

Authors:  M A Voelkel; K M Wynne; D B Badesch; B M Groves; N F Voelkel
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

5.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 7.  Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure.

Authors:  Corinna Bergamini; Mariantonietta Cicoira; Andrea Rossi; Corrado Vassanelli
Journal:  Eur J Heart Fail       Date:  2009-04-04       Impact factor: 15.534

8.  Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables.

Authors:  Edoardo Rosato; Stefania Maione; Antonio Vitarelli; Anna Giunta; Luca Fontanella; Laura Tanturri de Horatio; Francesco Cacciatore; Michele Proietti; Simonetta Pisarri; Felice Salsano
Journal:  Rheumatol Int       Date:  2008-12-28       Impact factor: 2.631

9.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

10.  Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis.

Authors:  Andriana I Papaioannou; Epaminondas Zakynthinos; Konstantinos Kostikas; Theodoros Kiropoulos; Angela Koutsokera; Athanasios Ziogas; Athanasios Koutroumpas; Lazaros Sakkas; Konstantinos I Gourgoulianis; Zoe D Daniil
Journal:  BMC Pulm Med       Date:  2009-05-09       Impact factor: 3.317

View more
  13 in total

1.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

2.  Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan.

Authors:  Le-Yung Wang; Kuang-Tso Lee; Chia-Pin Lin; Lung-An Hsu; Chun-Li Wang; Tsu-Shiu Hsu; Wan-Jing Ho
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 3.  Systemic sclerosis--challenges for clinical practice.

Authors:  Zsuzsanna H McMahan; Laura K Hummers
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

4.  Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Authors:  Gang Li; Yan Li; Xiao-Qiu Tan; Peng Jia; Jian Zhao; Dong Liu; Ting Wang; Bin Liu
Journal:  Pediatr Cardiol       Date:  2017-08-18       Impact factor: 1.655

5.  Increased serum uric acid levels are associated with digital ulcers in patients with systemic sclerosis.

Authors:  Eunsung Kim; Han-Na Lee; Yun-Kyung Kim; Geun-Tae Kim; Min Wook So; Eunyoung Ahn; Dong Hyun Sohn; Seung-Geun Lee
Journal:  Rheumatol Int       Date:  2019-01-17       Impact factor: 2.631

6.  Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis.

Authors:  M P Cruz-Domínguez; D H Montes-Cortes; I M Olivares-Corichi; O Vera-Lastra; G Medina; L J Jara
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

Review 7.  Uric acid in heart failure: a biomarker or therapeutic target?

Authors:  Marc Kaufman; Maya Guglin
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

8.  A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis.

Authors:  Yanjie Hao; Vivek Thakkar; Wendy Stevens; Kathleen Morrisroe; David Prior; Candice Rabusa; Peter Youssef; Eli Gabbay; Janet Roddy; Jennifer Walker; Jane Zochling; Joanne Sahhar; Peter Nash; Susan Lester; Maureen Rischmueller; Susanna M Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2015-01-18       Impact factor: 5.156

Review 9.  Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Authors:  Theodoros Dimitroulas; Aamer Sandoo; George D Kitas
Journal:  Int J Mol Sci       Date:  2012-09-26       Impact factor: 5.923

10.  Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study.

Authors:  Zsuzsanna McMahan; Florian Schoenhoff; Jennifer E Van Eyk; Fredrick M Wigley; Laura K Hummers
Journal:  Arthritis Res Ther       Date:  2015-08-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.